



Notice to Covered Entities Regarding JAKAFI®
Defined Distribution Network
June 2020

This notice provides information to 340B covered entities about how to acquire JAKAFI® (ruxolitinib) at 340B ceiling prices.¹

JAKAFI is an orphan drug approved to treat patients with: (1) intermediate or high-risk myelofibrosis; (2) polycythemia vera in patients who have had an inadequate response to or are intolerant of hydroxyurea; and (3) steroid-refractory acute graft-versus-host disease. To support high-quality care for patients taking JAKAFI, Incyte distributes the product through a defined network of specialty distributors and pharmacies.

Incyte offers the 340B price to all covered entities, except those that are ineligible for 340B pricing for orphan drugs as JAKAFI is designated for orphan use by the FDA.² Eligible 340B covered entities may purchase JAKAFI at the 340B price for delivery to the covered entities' facilities through Incyte's network of specialty distributors for JAKAFI: ASD Healthcare, Cardinal Health Specialty Distribution, and McKesson Plasma and Biologics. If a 340B covered entity does not have an in-house pharmacy capable of dispensing JAKAFI, then Incyte will support a contract pharmacy arrangement for that covered entity, if the pharmacy:

- Closely manages its patients' care;
- Has expertise in the treatment of oncology and provides patient access to oncology nurses;
- Offers programs to support patients' access to prescribed medications;
- Has distribution capabilities that comply with applicable law;
- Can report adverse events and other data to Incyte; and
- Possesses URAC³ accreditation.

These requirements match Incyte's criteria for evaluating specialty pharmacy requests to join the JAKAFI dispensing network and are designed to help ensure quality care for patients on JAKAFI.

Incyte takes seriously both its obligations to protect patient safety and to comply with the 340B statute, and has designed the defined distribution network for JAKAFI accordingly. The defined distribution network may change from time-to-time. If a covered entity has any questions regarding how it may access JAKAFI at the 340B price, please contact Incyte at Incyte_TradeandDistribution@incyte.com.

###

¹ This notice supersedes and provides minor updates to the HRSA website notice for JAKAFI dated June 2017.

² These covered entities are free-standing cancer hospitals, critical access hospitals, rural referral centers, and sole community hospitals. See 42 U.S.C. § 256b(e).

³ URAC is a nationally-recognized accreditor of specialty pharmacies.